Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 7/20 | 0.67 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.67 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.67 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | BRD4 | O60885 | 3/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.67 |
| ▸ | PTAFR | P25105 | 3/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | BRD2 | P25440 | 1/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407473 | 1.00 | GABRA1 (0.67) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL11829887 | 0.87 | LMNA (0.60) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL11681332 | 0.86 | GABRA1 (0.72) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL29392983 | 0.86 | GABRA1 (0.72) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL11621256 | 0.85 | GABRA1 (0.70) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL11354400 | 0.85 | OPRK1 (0.70) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL11861470 | 0.84 | LMNA (0.57) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL11379289 | 0.84 | LMNA (0.57) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL10403278 | 0.84 | LMNA (0.57) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL11828696 | 0.84 | LMNA (0.62) | GABRA1GABRA5GABRA2GABRB2GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3544597-A1 | THERAPIES FOR THE TREATMENT OF LIDOCAINE-INEFFECTIVE AND HYPOKALEMIC CONDITIONS | Alkalidx, Inc. (US) | 2019-10-02 | — | — | EP | claimed |
| WO-2018098273-A1 | THERAPIES FOR THE TREATMENT OF LIDOCAINE-INEFFECTIVE AND HYPOKALEMIC CONDITIONS | ALKALIDX, INC. (US) | 2018-05-31 | — | — | WO | claimed |
| US-3987052-A | SEDATIVES, TRANQUILIZERS, MUSCLE RELAXANTS | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-20260116853-A1 | NEW N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | ATAI THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2026-04-28 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20250388538-A1 | N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | ATAI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250367223-A1 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2025-12-04 | — | — | US | disclosed |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | CYBIN IRL LIMITED (IE) | 2025-11-27 | — | — | US | disclosed |
| US-12447164-B2 | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2025-10-21 | — | — | US | disclosed |
| US-20200316087-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2020-10-08 | — | — | US | disclosed |
| WO-2020056117-A1 | IMPROVING SLEEP OR POST-SLEEP PERFORMANCE | VANDA PHARMACEUTICALS INC.. (US) | 2020-03-19 | — | — | WO | disclosed |
| EP-3544597-A1 | THERAPIES FOR THE TREATMENT OF LIDOCAINE-INEFFECTIVE AND HYPOKALEMIC CONDITIONS | Alkalidx, Inc. (US) | 2019-10-02 | — | — | EP | disclosed |
| CN-110191706-A | The treatment method for treating lidocaine invalid illness and hypokalemia illness | 阿卡利德公司 | 2019-08-30 | — | — | CN | disclosed |
| WO-2019070910-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | UWM RESEARCH FOUNDATION, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2018098273-A1 | THERAPIES FOR THE TREATMENT OF LIDOCAINE-INEFFECTIVE AND HYPOKALEMIC CONDITIONS | ALKALIDX, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| US-4102881-A | REACTING 2-AMINOBENZOPHENONES WITH ALKYL ORTHO-HALO-ACETATE THEN WITH AN ALKALI METAL AZIDE, SUBJECTING TO REDUCTIVE RING CLOSURE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1978-07-25 | — | — | US | disclosed |
| US-4000289-A | 6-PHENYL-4H-S-TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINES | THE UPJOHN COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
| US-3987052-A | SEDATIVES, TRANQUILIZERS, MUSCLE RELAXANTS | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | GABRA1 879/4885GABRA5 1254/4885GABRA2 818/4885 |
| US-20250360148-A1 | SOLID DISPERSIONS OF PSILOCYBIN | HTR2B, HTR2A, HTR2C | GABRA1 1643/4885GABRA5 1577/4885GABRA2 844/4885 |
| US-20260116853-A1 | NEW N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | SLC6A4, HTR1D, HTR1A | GABRA1 4236/4885GABRA5 4312/4885GABRA2 4149/4885 |
| US-20250388538-A1 | N,N-DIMETHYLTRYPTAMINE SALTS AND CRYSTALLINE SALT FORMS | SLC6A4, SLC6A2, SLC18A2 | GABRA1 4084/4885GABRA5 4012/4885GABRA2 3859/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | GABRA1 1184/4885GABRA5 1883/4885GABRA2 1150/4885 |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | HTR1D, HTR1B, HTR2B | GABRA1 671/4885GABRA5 642/4885GABRA2 604/4885 |
| US-20200316087-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | GABRB2, GABRB1, GABRB3 | GABRA1 5/4885GABRA5 15/4885GABRA2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.